Table 2.
Response to M+R treatment (all patients and patient subsets)
| n (%) | All patients (N = 99) | Refractory to last regimen (n = 78) | Prior LOT |
Age, y |
Immunophenotype |
||||
|---|---|---|---|---|---|---|---|---|---|
| 1 (n = 5) | 2 (n = 37) | >2 (n = 57) | <75 (n = 64) | ≥75 (n = 35) | Germinal center (n = 56) | Nongerminal center (n = 22) | |||
| ORR∗ | 24 (24.2) | 15 (19.2) | 1 (20.0) | 9 (24.3) | 14 (24.6) | 16 (25.0) | 8 (22.9) | 11 (19.6) | 5 (22.7) |
| CR | 12 (12.1) | 6 (7.7) | 0 | 4 (10.8) | 8 (14.0) | 9 (14.1) | 3 (8.6) | 4 (7.1) | 3 (13.6) |
| PR | 12 (12.1) | 9 (11.5) | 1 (20.0) | 5 (13.5) | 6 (10.5) | 7 (10.9) | 5 (14.3) | 7 (12.5) | 2 (9.1) |
| SD | 10 (10.1) | 7 (9.0) | 0 | 4 (10.8) | 6 (10.5) | 7 (10.9) | 3 (8.6) | 6 (10.7) | 2 (9.1%) |
| PD | 52 (52.5) | 45 (57.7) | 2 (40.0) | 17 (45.9) | 33 (57.9) | 39 (60.9) | 13 (37.1) | 30 (53.6) | 12 (54.5) |
| NE | 1 (1.0) | 1 (1.3) | 1 (20.0) | 0 | 0 | 0 | 1 (2.9) | 1 (1.8) | 0 |
| NA† | 12 (12.1) | 10 (12.8) | 1 (20.0) | 7 (18.9) | 4 (7.0) | 2 (3.1) | 10 (28.6) | 8 (14.3) | 3 (13.6) |
LOT, line of therapy; NA, not assessed; NE, not evaluable; SD, stable disease.
∗
Per Lugano criteria.
†
Patients with no postbaseline overall assessment.